Page 10 - Ram Prasad Sahu/workspace/business Standard Web/video

Hospital valuations keep steady pulse, ensuring growth never skips a beat

Administering the right dose for asset-light expansion and steady margins

Outlook for Wipro trimmed after weak guidance, muted Q4 revenue show

India's fourth largest software company continues to underperform compared to peers

Automobiles to pharma & healthcare: Earnings winter to persist in Q4FY25

Past champions such as banks, oil & gas and automotive seen as laggards

Multiple headwinds to keep tiles sector under pressure in the near term

The ultra-luxury apartments demonstrate significant demand, driven by rising disposable incomes and a preference for high-end options

Stock downfall: The side effects are real, but Sun Pharma stays on its feet

Growth hormone kicks in as India's largest pharma firm's vital signs hold amid generic strain

Near-term headwinds may keep Metropolis Healthcare under pressure

The near-term triggers for the stock are the March quarter (Q4FY25) performance and the acquisition of Dr Ahujas' Pathology and Imaging Centre (DAPIC) earlier this week

FMCG stocks gain as RBI cuts FY26 inflation est; GCPL, HUL rise up to 2%

The RBI MPC, on Wednesday, unanimously decided to cut the repo rate by 25 basis points, bringing it down to 6 per cent, from 6.25 per cent earlier.

IndiGo stock hits all-time high; surges 12% in 1-month on healthy outlook

The brokerage has been structurally positive on IndiGo driven by business moats of cost competitiveness, robust orderbook and strong balance sheet

Growth worries, competitive pressures weigh on Trent stock performance

Elara Securities expects gross margin for the March quarter to come down by 71 basis points quarter-on-quarter and 129 basis points year-on-year due to seasonality

Warning lights flash for ER&D companies as auto sector runs low on fuel

ER&D downshifts on weak Q4, gloomy 2025; more downgrades loom

Pharma companies likely to pass on costs in US as fresh levy looms

Brokerages also felt that the pharma companies will aim to pass on the tariff hike to payors

Higher tariffs may significantly dent profits of pharma companies

Companies such as Sun Pharma which have a significant specialty portfolio could be less impacted than Indian peers in the US market given lower competition in niche segments

Fizz is back in Varun Beverages stock as launches, summer boost outlook

The key concern weighing on the stock is increased competitive intensity with the relaunch of Campa Cola by Reliance Consumer Products (RCPL) in March 2023

Pharmaceutical growth cure lies in CDMOs' resilience to market ailments

They get growth Rx from outsourcing, with fewer Trump tariff side effects

Reits climb the office ladder even as valuations keep rungs in place

Realty index in the rearview as office demand pulls Reits out of a two-year slump

Varun Beverages' stock correction overdone; growth prospects strong

The Street believes that the correction is overdone and that the company has multiple growth opportunities in India and the African market

Indian defence sector stocks lock and load, ready for export offensive

Investor firepower reloaded, targeting domestic growth, exports, and European rearmament

From Bajaj Finance to Wipro: Stocks that sailed through market storm

The sell-off has been across the board with 185 or 92.5 per cent of all Nifty 200 stocks witnessing a price decline and 68.5 per cent (137 of 200) falling 15 per cent or more during this period

Despite near-term challenges, brokerages remain positive on Sun Pharma

The recent trigger for the stock is the acquisition of US-based Checkpoint Therapeutics

Expected heatwave to thaw the freeze on air conditioner stock gains

DEMAND BOILS OVER, PRICE HIKES SIZZLE: Room air conditioner majors eye scorching double-digit growth